Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

• Published in: Journal of palliative medicine Vol. 9; no. 1; p. 29
• Main Authors: Raskin, Joel, Smith, Timothy R, Wong, Kar, Pritchett, Yili Lu, D'Souza, Deborah N, Iyengar, Smriti, Wernicke, J F
• Format: Journal Article
• Language: English
• Published: United States 01.02.2006
• Subjects: Amines - adverse effects; Amines - therapeutic use; Amitriptyline - adverse effects; Amitriptyline - therapeutic use; Analysis of Variance; Cyclohexanecarboxylic Acids - adverse effects; Cyclohexanecarboxylic Acids - therapeutic use; Cyclohexanols - adverse effects; Cyclohexanols - therapeutic use; Diabetic Neuropathies - drug therapy; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; gamma-Aminobutyric Acid - adverse effects; gamma-Aminobutyric Acid - therapeutic use; Humans; Male; Middle Aged; Serotonin Uptake Inhibitors - adverse effects; Serotonin Uptake Inhibitors - therapeutic use; Thiophenes - adverse effects; Thiophenes - therapeutic use; Treatment Outcome; Venlafaxine Hydrochloride

Duloxetine hydrochloride is a dual reuptake inhibitor of both serotonin and norepinephrine. In the present open-label study, the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks was evaluated and compared to routine care in the therapy of patients diagnosed with dia...